DNA methylation assay for colorectal carcinoma

Area of Science:

• Oncology
• Epigenetics
• Molecular Diagnostics

Background:

• Colorectal carcinoma (CRC) is a significant global health burden.
• CRC develops through distinct pathways, including chromosomal instability and DNA mismatch repair gene defects.
• Aberrant DNA methylation is an emerging epigenetic mechanism in CRC development.

Purpose of the Study:

• To explore the potential of DNA methylation biomarkers in stool for colorectal cancer screening.
• To evaluate the diagnostic accuracy of specific methylated genes in early-stage CRC and adenoma detection.

Main Methods:

• Analysis of DNA methylation patterns in stool samples from CRC and adenoma patients.
• Investigation of specific methylated genes, such as secreted frizzled-related protein 2 and vimentin.
• Application of quantitative real-time polymerase chain reaction (qPCR) for sensitive biomarker detection.

Main Results:

• Multiple DNA methylation biomarkers have been identified in stool associated with CRC and adenoma.
• Certain biomarkers demonstrate high sensitivity and specificity for detecting precursor lesions and cancer.
• Stool-based DNA methylation analysis using qPCR offers a promising screening approach.

Conclusions:

• DNA methylation biomarkers in stool represent a viable strategy for enhancing colorectal cancer screening.
• These biomarkers hold potential for the early diagnosis of CRC and adenoma.
• A stool qPCR methylation test could serve as an effective tool for population-based screening.